Get started
Work

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Year: 2022
Type: article
Abstract: = 0.079). Among 8 cases in the cefiderocol group who experienced microbiological failure, 4 (50%) developed resistance to cefiderocol. Cefiderocol represents a promising therapeutic option in patients with severe CRAB infections. Randomized clinical trial in this specific patient population should confirm our findings.
DOI: 10.1128/aac.02142-21
Authors: Marco Falcone, Giusy Tiseo, Alessandro Leonildi, Leonardo Della Sala, Alessandra Vecchione, Simona Barnini, Alessio Farcomeni, Francesco Menichetti
Language: English
Field: Medicine
Open Access status: green
Funders: Bristol-Myers Squibb, Pfizer, Gilead Sciences, Astellas Pharma, Shionogi, Nordic Pharma Group
OpenAlex ID: W4220764592
FWCI: 18.98
Cites: 33
Cited by: 197
Related to: 10